EMERGENT BIOSOLUTIONS INC. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
EMERGENT BIOSOLUTIONS INC. (EBS) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $6.70 million for the 12-month period ending 2022-12-31, per its 10-K/A filed 2023-12-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2023-12-11
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2021-12-31 was $41.70M.
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2019-12-31 was $12.00M.
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2016-12-31 was $701.00K.
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2022 was $6.70M, a 83.93% decline from fiscal 2021.
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2021 was $41.70M, a 43.79% increase from fiscal 2020.
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2020 was $29.00M, a 141.67% increase from fiscal 2019.
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2019 was $12.00M.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2022-12-31 | $6.70M 10-K/A · filed 2023-12-11 | |||
| 2021-12-31 | $41.70M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $41.70M 10-K/A · filed 2023-12-11 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-05 | |||
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $29.00M 10-K/A · filed 2023-12-11 | ||
| 2020-09-30 | $29.00M 10-Q · filed 2021-11-05 | |||
| 2019-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $12.00M 10-K · filed 2022-02-25 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-06 | |||
| 2017-12-31 | $0.00 10-K · filed 2018-02-23 | |||
| 2016-12-31 | $701.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $701.00K 10-K · filed 2018-02-23 | ||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-09 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $9.83M 10-K · filed 2018-02-23 | ||
| 2015-09-30 | $9.83M 10-Q · filed 2016-11-09 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $0.00 10-K · filed 2017-02-28 | ||
| 2014-09-30 | $0.00 10-Q · filed 2015-11-06 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $0.00 derived: sum of 3 quarters · filed 2016-02-29 | $0.00 10-K · filed 2016-02-29 |
| 2013-09-30 | $0.00 10-Q · filed 2013-11-08 | $0.00 derived: sum of 2 quarters · filed 2013-11-08 | $0.00 10-Q · filed 2013-11-08 | $0.00 derived: sum of 4 quarters · filed 2015-03-09 |
| 2013-06-30 | $0.00 10-Q · filed 2013-08-06 | $0.00 10-Q · filed 2013-08-06 | $0.00 derived: sum of 3 quarters · filed 2015-03-09 | $0.00 derived: sum of 4 quarters · filed 2015-03-09 |
| 2013-03-31 | $0.00 10-Q · filed 2013-05-03 | $0.00 derived: sum of 2 quarters · filed 2015-03-09 | $0.00 derived: sum of 3 quarters · filed 2015-03-09 | $0.00 derived: sum of 4 quarters · filed 2015-03-09 |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $0.00 derived: sum of 2 quarters · filed 2015-03-09 | $0.00 derived: sum of 3 quarters · filed 2015-03-09 | $9.60M 10-K · filed 2015-03-09 |
| 2012-09-30 | $0.00 10-Q · filed 2013-11-08 | $0.00 derived: sum of 2 quarters · filed 2013-11-08 | $9.60M 10-Q · filed 2013-11-08 | $9.60M derived: sum of 4 quarters · filed 2014-03-10 |
| 2012-06-30 | $0.00 10-Q · filed 2013-08-06 | $9.60M 10-Q · filed 2013-08-06 | $9.60M derived: sum of 3 quarters · filed 2014-03-10 | $9.60M derived: sum of 4 quarters · filed 2014-03-10 |
| 2012-03-31 | $9.60M 10-Q · filed 2013-05-03 | $9.60M derived: sum of 2 quarters · filed 2014-03-10 | $9.60M derived: sum of 3 quarters · filed 2014-03-10 | $9.60M derived: sum of 4 quarters · filed 2014-03-10 |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $0.00 derived: sum of 2 quarters · filed 2014-03-10 | $0.00 derived: sum of 3 quarters · filed 2014-03-10 | $0.00 10-K · filed 2014-03-10 |
| 2011-09-30 | $0.00 10-Q · filed 2012-11-01 | $0.00 derived: sum of 2 quarters · filed 2012-11-01 | $0.00 10-Q · filed 2012-11-01 | |
| 2011-06-30 | $0.00 10-Q · filed 2012-08-03 | $0.00 10-Q · filed 2012-08-03 | ||
| 2011-03-31 | $0.00 10-Q · filed 2012-05-04 | |||
| 2010-12-31 | $0.00 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |